ReviewCell genomics2026
Mitotic and meiotic midbody remnants: Divergent architectures with distinct clinical applications.
Review in Cell genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Midbody remnants (MBRs), once considered inert cytokinetic debris, are now recognized as architecturally specialized, translationally active organelles whose functions reflect the mode of cell division. This review compares MBR biology in symmetric somatic mitosis and asymmetric oocyte meiosis. In somatic cells, MBRs can be retained or secreted as large extracellular vesicles that carry midbody proteins, RNAs, and translation machinery; their enrichment in stem and cancer cells implicates them in cell-state regulation and identifies them as promising, though unvalidated, substrates for liquid-biopsy biomarkers and therapeutic targeting. In oocytes, meiotic midbodies form a distinctive ring-cap architecture that concentrates local translation and restricts maternal products to the egg, thereby supporting developmental competence. Together, these studies establish division mode as a key determinant of midbody architecture, cargo, fate, and translational potential, linking cytokinesis to cancer biology and reproductive medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.